233 results about "Antibody molecule" patented technology

The disclosure provides compositions and methods for the preparation, manufacture and use of an adeno-associated virus (AAV) particle for the vectorized delivery of an antibody molecule that binds to tau.

The invention discloses an anti-CLDN6 nano antibody and related application thereof, and relates to the field of antibodies. The invention provides an anti-CLDN6 nano antibody, which comprises HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of which the amino acid sequence is as shown in SEQ ID NO: 4, the nano antibody has excellent antigen binding activity, high specificity and good affinity, has relatively strong killing activity on cells with high expression of CLDN6, and can be used for preparing anti-CLDN6 drugs. The requirements of CLDN6 positive tumor immunotherapy on efficient, specific and high-penetrability antibody molecules are met, and a new strategy and means are provided for tumor therapy.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The invention provides a preparation method and application of a CD70 specific nano antibody molecular imaging probe. The probe comprises a tumor targeting group, radionuclide and a bifunctional chelating agent, the tumor targeting group is a CD70 specific nano antibody; the CD70 specific nano antibody is R8B4, and the amino acid sequence of the R8B4 is as shown in SEQ ID No. 1. The probe provided by the invention can realize noninvasive diagnosis of solid tumors such as renal clear cell carcinoma and malignant tumors of a blood system; reabsorption of the compound in the kidney is effectively inhibited through charge adjustment, kidney uptake is remarkably reduced, non-specific signals are reduced, the signal-to-noise ratio during targeted imaging or treatment is increased, and the imaging quality and treatment safety are improved. The probe not only has a wide application prospect in tumor diagnosis, but also provides a new technical support for targeted therapy and individualized precision medical treatment, and has important scientific research and clinical application values.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

Provided herein are anti-Programmed Death-Ligand (PD-L1) antibodies, antigen-binding fragments thereof, multispecific antibodies and encoding polynucleotides. Also provided are PD-L1-targeted phthalocyanine dye conjugates, compositions and articles of manufacture containing the conjugates, and methods for their administration to subjects for photoimmunotherapy. In some embodiments, the anti-PD-L1 antibodies, fragments, and conjugates specifically bind to human PD-L1. Among the anti-PD-L1 antibodies are human antibodies and humanized antibodies. Also provided are methods and uses employing the provided anti-PD-L1 antibodies, antigen-binding fragments, and conjugates such for treatment of human patients.

The present invention relates to the combined use of FcyRIIb (CD32B)- and CD20-specific antibodies, in particular to a method of treating a patient having target cells expressing FcyRIIb, the method comprising the combined administration of: (i) an antibody molecule specifically binding to a surface antigen of said target cells, said antibody molecule having an Fc domain capable of binding to FcyRIIb; and (ii) an agent inhibiting or reducing the binding between the Fc domain of said antibody molecule and FcyRIIb, characterized in that the patient is selected on the basis of an elevated level of FcyRIIb expression by his target cells.

The invention discloses a nano antibody targeting GPRC5D as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nano antibody is generated by mixed immunization of a GPRC5D polypeptide antigen with a sequence shown as SEQ ID NO: 1 and a GPRC5D protein antigen with a sequence shown as SEQ ID NO: 2. The preparation method comprises the following steps: mixing the GPRC5D polypeptide antigen and the GPRC5D protein antigen to immunize alpaca, sampling blood, constructing an antibody library, screening a phage display antibody library, expressing protein, and selecting the nano antibody with the highest affinity. The invention further provides a radionuclide labeled molecular probe, the nano antibody is small in molecular weight and can recognize a large number of epitopes, and the molecular probe prepared from the nano antibody can obtain high-quality images, is used for preparing products for developing multiple myeloma or detecting GPRC5D expression level and has wide application prospects.

The present invention provides a method for identifying multifactorial interactions in a biological sample, comprising (a) selecting a plurality of analytical target factors, (b) labeling antibody molecules against each of the selected factors with DNA barcodes, (c) contacting a biological sample containing the analytical target factors with the antibody molecules labeled with the DNA barcodes, (d) embedding the biological sample in a hydrogel after step (c), (e) performing, within the hydrogel, a nucleic acid amplification reaction using a plurality of primers designed such that, when two antibodies come in close proximity, the primers produce an amplification product containing both DNA barcode sequences from the antibodies, and (f) analyzing a nucleotide sequence of the produced amplification product to detect a presence of a factor that simultaneously interacts with two or more factors.

The invention belongs to the technical field of biology, and particularly relates to a swine monoclonal antibody of hog cholera virus Erns protein. The amino acid sequence of a heavy chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 1, the amino acid sequence of a heavy chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 2, the amino acid sequence of a light chain variable region of the swine monoclonal antibody is shown as SEQ ID NO: 3, and the amino acid sequence of the light chain constant region of the swine monoclonal antibody is shown as SEQ ID NO: 4. The full-length genes of the heavy chain and the light chain of the swine monoclonal antibody are obtained from a swine B cell specifically amplified by the same hog cholera virus Erns protein, the natural structure of an antibody molecule is reserved, affinity loss possibly caused by artificial recombination is avoided, and the swine monoclonal antibody has high affinity and specificity, and can be used for preparing the swine monoclonal antibody. And a precise molecular tool is provided for antigen structure analysis of the hog cholera virus Erns protein and establishment of a hog cholera diagnosis method. The monoclonal antibody is applied to a blocking ELISA detection method of the hog cholera virus Erns antibody, and the established Erns antibody blocking ELISA detection method is high in sensitivity and strong in specificity.

The disclosure provides compositions and methods for the preparation, manufacture and use of an adeno-associated virus (AAV) particle for the vectorized delivery of an antibody molecule that binds to HER2.

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to a method of administering a BCMA-targeting agent which is an anti-BCMA antibody molecule or a recombinant non-antibody protein that binds to BCMA, and a gamma secretase inhibitor.

The present disclosure relates to a method for the manufacture of recombinant antibody molecules comprising culturing a host cell sample transformed with an expression vector encoding a recombinant antibody molecule; adding an extraction buffer to the sample; and subjecting the sample to a heat treatment step; wherein the pH of the sample is detected after addition of the extraction buffer, and optionally adjusted, to ensure that the pH of the sample is 6 to 9 prior to the heat treatment step.

The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm−2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, meth

Provides herein are compositions comprising an agent that comprises an antigen binding domain that binds to NKp30, and methods of treating conditions or diseases in a subject and methods of expanding and / or activation NK cells using the same.

The invention relates to a fluorescently-labeled Prussian blue nano-particle as well as a preparation method and application thereof, the fluorescently-labeled Prussian blue nano-particle is prepared, and a carboxyl functional group is reserved on the surface of the nano-particle and is used for being subsequently coupled with an antigen or antibody molecule through a covalent bond. The nano material can provide colorimetric and fluorescent dual-mode detection functions, is beneficial to enhancing the detection sensitivity of an immunochromatography technology, and meanwhile, retains the detection convenience. The material is simple in preparation method, low in cost and easy for large-scale production and application.

The invention relates to an antibody specifically binding to TROP2 or an antigen binding fragment thereof. The invention also encompasses VHH antibodies or heavy chain antibodies that specifically bind to PD-L1. The invention further relates to a bispecific antibody which is constructed on the basis of the TROP2 antibody and the PD-L1 antibody and is specifically combined with the TROP2 and the PD-L1. The invention also encompasses immunoconjugates constructed based on the antibody molecules, such as antibody-conjugated drugs such as ADC. The invention further relates to a preparation method and application of the antibody molecule and the TROP2xPD-L1 targeting bispecific antibody coupling medicine.

Antibody molecules that specifically bind to LAG-3 are disclosed. The anti-LAG-3 antibody molecules can be used to treat, prevent and / or diagnose cancerous or infectious disorders.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-CD20 antibody, such as e.g. Rituximab, Ocrelizumab, or HuMab<CD20>, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-CD20 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The said formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

Antibody molecules that specifically bind to NKp30 are disclosed. The anti-NKp30 antibody molecules can be used to treat, prevent and / or diagnose cancerous, autoimmune or infectious conditions and disorders.

Disclosed herein are modified human interleukin-2 (hIL-2) proteins, human antibody molecules, or antigen-binding fragments thereof, that immunospecifically bind to human programmed cell death protein-1 (hPD-1), and immunoconjugates comprising the same.

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

The combined use of a first antibody molecule that specifically binds to Fc [gamma] RIIb through its Fab region and binds to Fc [gamma] receptor through its Fc region and a second antibody molecule that specifically binds to PD-1 and binds to at least one Fc [gamma] receptor through its Fc region in the treatment of cancer in a patient having tumor-infiltrating T lymphocytes having medium or high PD-1 expression is described, as well as pharmaceutical compositions and kits comprising these two antibody molecules, as well as methods of using these two antibodies to treat cancer. A diagnostic test for identifying patients who benefit from the treatment described herein is also described.

Provided herein are antibody molecules that bind specifically to Programmed cell death 1 (PD1) and Vascular endothelial growth factor receptor 2 (VEGFR2), related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules.

The present invention relates to monospecific or bispecific antibody molecules that specifically bind antigens of Death Receptors, which are members of the tumor necrosis factor (TNF) receptor Superfamily (TNFR-SF) with an intracellular death domain. The invention relates in particular to antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after target binding. The invention further relates to a combination of antibody molecules binding different epitopes on one or more specific Death Receptors. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.